샘플 요청 목록

 카트 문의
시장보고서
상품코드
1784812

세계의 요로질환 치료 시장

Uropathy Treatment
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 271 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 요로질환 치료 시장은 2030년까지 53억 달러에 도달

2024년에 44억 달러로 추정되는 요로질환 치료 세계 시장은 2024-2030년 분석 기간에 CAGR 3.0%로 성장하여 2030년에는 53억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 스텐트는 CAGR 3.7%를 나타내고, 분석 기간 종료까지 35억 달러에 이를 것으로 예측됩니다. 디바이스 분야의 성장률은 분석 기간중 CAGR 1.7%로 추정됩니다.

미국 시장은 12억 달러로 추정, 중국은 CAGR 5.8%로 성장 예측

미국의 요로질환 치료 시장은 2024년에 12억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 분석 기간인 2024-2030년간 CAGR 5.8%로 2030년까지 10억 달러 규모에 이를 것으로 예측됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 1.1%와 2.3%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 1.7%를 보일 전망입니다.

세계의 요로질환 치료 시장 - 주요 동향과 촉진요인 정리

비뇨기과 질환 부담 증가로 종합적인 요로질환 치료 수요 증가?

폐색성 요로질환과 요로감염(UTI)에서 신경인성 방광, 방광 출구 폐쇄, 신장 석회화까지 비뇨기과 질환의 전 세계 부담은 전례 없는 속도로 증가하고 있으며, 전 세계 의료 시스템에서 요로질환 치료에 대한 큰 수요를 주도하고 있습니다. 인구의 고령화, 당뇨병, 비만, 고혈압 등의 합병증이 만연함에 따라 배뇨장애와 하부요로장애의 발생률은 지속적으로 증가하고 있습니다. 또한, 구조적 이상, 재발성 감염, 수술 후 합병증, 외상 등이 전문적인 요로 관리가 필요한 환자 증가로 이어지고 있습니다. 이 때문에 카테터 치료, 외과적 개입, 신경 조절, 지지 요법 등 약리학적 및 비약리학적 치료 전략이 눈에 띄게 증가하고 있습니다. 급성 및 만성 모두에서 돌이킬 수 없는 신손상, 패혈증, 수족구병과 같은 합병증을 예방하기 위해서는 조기 개입이 중요합니다. 진단 능력이 향상되고 더 많은 사례를 조기에 발견할 수 있게 됨에 따라, 의료 서비스 제공업체들은 치료에 대한 다학제적 접근을 더욱 중요하게 여기고 있습니다. 신장 전문의, 재활의학과 전문의, 일반의가 점점 더 많은 협진 진료 모델에 참여하고 있으며, 이는 모든 수준의 진료에서 종합적인 요로질환 치료 솔루션에 대한 복잡성과 수요가 증가하고 있음을 반영합니다.

외과적, 내과적, 지지요법의 혁신은 치료의 상황을 어떻게 변화시키고 있는가?

요로질환 치료의 전망은 수술 기술, 약물 치료, 의료기기 혁신의 발전으로 빠르게 변화하고 있습니다. 요관경, 경피적 신결석 제거술(PCNL), 레이저 결석파쇄술, 복강경 비뇨기 재건술과 같은 최소침습 수술은 빠른 회복과 입원기간 단축, 더 나은 환자 예후를 가능하게 하고 있습니다. 이러한 접근법은 결석, 종양, 해부학적 이상으로 인한 폐쇄성 요로장애 치료에 특히 유용합니다. 약리학적 측면에서는 α차단제, 항무스카린제, β3 아드레날린 작용제와 같은 새로운 약물이 방광 출구 폐쇄 및 과민성 방광 증후군의 치료에 사용되는 치료법의 폭을 넓혀가고 있습니다. 한편, 보툴리눔툭신(보톡스) 주사와 천골 신경 자극의 사용은 신경인성 요로장애의 치료에 널리 사용되고 있습니다. 카테터 기술도 진화하고 있으며, 감염 위험을 줄이고 환자의 편안함을 향상시키는 항균성, 친수성 코팅, 간헐성 카테터의 도입이 진행되고 있습니다. 또한, 착용형 소변 센서, 휴대용 방광 스캐너, 원격 환자 모니터링 도구는 치료 후 감시 및 만성 요로질환 관리에서 점점 더 큰 역할을 하고 있습니다. 디지털 플랫폼은 현재 환자의 순응도와 증상 추적을 지원하고, 3D 영상과 내비게이션 시스템의 혁신은 수술의 정확성을 높이고 있습니다. 이러한 개발로 인해 보다 개인화되고 기술적으로 통합된 치료 환경이 조성되고 있으며, 환자와 의료진 모두 보다 효과적이고 효율적으로 요로질환을 관리할 수 있게 되었습니다.

예방 치료와 조기 개입 전략이 요로질환에 대한 장기적인 접근법을 재정의할 수 있을까?

예방의학은 특히 피할 수 있는 입원, 외과적 개입, 만성 신장 합병증 감소에 중점을 둔 의료 시스템에서 요로질환 치료 전략의 중심이 되고 있습니다. 신장 기능, 요로폐색, 방광 기능 장애에 대한 정기적인 스크리닝을 통한 조기 발견은 돌이킬 수 없는 장애가 발생하기 전에 임상의가 개입할 수 있게 해줍니다. 당뇨병 환자, 척수 손상 환자, 노인 등 위험에 노출된 사람들을 대상으로 한 교육 활동을 통해 배뇨 곤란, 빈뇨, 요폐, 요실금 등의 증상을 조기에 보고하도록 장려하고 있습니다. 한편, 식습관 개선, 수분 보충 관리, 골반저근육 운동, 체중 관리 등의 생활습관 중재는 요로장애의 발병과 진행을 억제하기 위한 1차적 전략으로 추진되고 있습니다. 이러한 접근법은 하부요로증상(LUTS) 및 경미한 신경인성 방광 또는 기립성 조절 장애의 관리에 특히 효과적입니다. 소아과에서는 비침습적 영상진단과 저외상성 수술적 수복으로 선천성 요로장애를 적시에 개선하여 장기적인 신기능 장애의 위험을 최소화하고 있습니다. 원격 의료는 원격 진료, 조기 진단, 디지털 순응도 도구를 통해 예방적 요로질환 치료를 촉진하는 역할도 증가하고 있습니다. 조기 개입을 통한 경제적 이익과 삶의 질 향상을 뒷받침하는 임상적 증거가 늘어남에 따라, 지불자와 의료 제공업체 모두 종합적인 요로질환 관리의 일환으로 예방적 의료 프로토콜을 채택하고 있습니다.

요로질환 치료 세계 시장의 지속적인 성장을 가속하는 요인은 무엇인가?

요로질환 치료 시장의 성장은 만성질환 관리 및 개인 맞춤형 치료의 광범위한 추세를 반영하는 인구통계학적, 임상적, 기술적, 시스템적 요인의 수렴에 의해 이루어지고 있습니다. 특히 당뇨병, 척수손상, 신경장애, 암 등 배뇨기능을 저하시키고 장기적인 요로질환 치료를 필요로 하는 만성질환의 발생률이 높아지는 것이 주요 성장 요인입니다. 북미, 유럽, 아시아태평양의 고령화는 비뇨기과적 개입이 필요한 환자 증가에 더욱 기여하고 있습니다. 이에 따라 의료 시스템은 비뇨기과 서비스 라인을 확장하고 수요 증가에 대응하기 위해 수술 인프라, 진단, 외래 치료 모델에 투자하고 있습니다. 최소침습 수술과 로봇 보조 수술 기법의 발전으로, 특히 환자 수가 많은 센터에서는 첨단 치료 옵션에 대한 접근성이 향상되고 있습니다. 규제 당국의 신약 및 의료기기 승인은 유리한 상환 정책과 함께 시장 접근성과 경제성을 높여주고 있습니다. 요로 역학, 카테터 디자인, 신경조절 분야의 혁신은 다양한 중증도 수준의 요로 장애에 대한 치료 옵션을 더욱 넓혀주고 있습니다. 또한, 외래진료, 재택진료, 원격의료 지원을 통한 사후관리로의 전환은 진료의 연속성을 보장하면서 입원비용을 절감하는 데 도움이 되고 있습니다. 또한, 환자 교육 캠페인과 낙인 제거를 위한 노력은 의료 시스템에 조기 참여를 유도하여 진단율과 치료율을 향상시키는데 기여하고 있습니다. 이러한 힘의 관계가 지속되는 가운데, 세계 요로질환 치료 시장은 임상적 니즈 증가, 치료 패러다임의 진화, 다학제적이고 첨단 기술을 활용한 치료 솔루션에 대한 접근성 확대 등을 원동력으로 지속적이고 장기적인 성장이 예상됩니다.

부문

치료 유형(스텐트, 디바이스);최종사용자(병원 및 클리닉, 외래수술센터(ASC), 기타)

조사 대상 기업 예

  • AngioDynamics
  • Applied Medical
  • Argon Medical Devices, Inc.
  • Astellas Pharma Inc.
  • B. Braun Melsungen AG
  • Bayer AG
  • Becton, Dickinson and Company(BD)
  • Boston Scientific Corporation
  • Cook Medical
  • C. R. Bard, Inc.(a subsidiary of BD)
  • GlaxoSmithKline Pharmaceuticals Ltd.
  • Inceler Medikal Co. Ltd.
  • KARL STORZ
  • Merit Medical Systems, Inc.
  • Olympus Corporation
  • optimed
  • Pfizer Inc.
  • Purdue Pharma
  • Sanofi
  • Teleflex Incorporated

AI 통합

당사는 유효한 전문가 컨텐츠와 AI툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 일반적인 LLM나 업계별 SLM 쿼리에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH

Global Uropathy Treatment Market to Reach US$5.3 Billion by 2030

The global market for Uropathy Treatment estimated at US$4.4 Billion in the year 2024, is expected to reach US$5.3 Billion by 2030, growing at a CAGR of 3.0% over the analysis period 2024-2030. Stents, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$3.5 Billion by the end of the analysis period. Growth in the Devices segment is estimated at 1.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 5.8% CAGR

The Uropathy Treatment market in the U.S. is estimated at US$1.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.0 Billion by the year 2030 trailing a CAGR of 5.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.1% and 2.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.

Global Uropathy Treatment Market - Key Trends & Drivers Summarized

Is the Rising Burden of Urological Disorders Fueling Demand for Comprehensive Uropathy Treatment?

The global burden of urological diseases-ranging from obstructive uropathy and urinary tract infections (UTIs) to neurogenic bladder, bladder outlet obstruction, and renal calculi-is escalating at an unprecedented rate, driving significant demand for uropathy treatment across healthcare systems worldwide. As populations age and comorbidities such as diabetes, obesity, and hypertension become more prevalent, the incidence of urinary dysfunctions and lower urinary tract disorders continues to rise. In addition, structural anomalies, recurrent infections, post-surgical complications, and trauma-related injuries are contributing to the growing pool of patients requiring specialized uropathy management. This has triggered a marked increase in both pharmacologic and non-pharmacologic treatment strategies, including catheterization, surgical interventions, neuromodulation, and supportive therapies. In both acute and chronic cases, early intervention is critical to prevent irreversible kidney damage, sepsis, or complications such as hydronephrosis. As diagnostic capabilities improve and more cases are identified earlier, healthcare providers are placing greater emphasis on tailored, multidisciplinary approaches to treatment. Uropathy is no longer managed solely by urologists; nephrologists, rehabilitation specialists, and general practitioners are increasingly involved in coordinated care models, reflecting the complexity and rising demand for comprehensive uropathy treatment solutions across all levels of care.

How Are Innovations in Surgical, Medical, and Supportive Therapies Transforming the Treatment Landscape?

The landscape of uropathy treatment is being rapidly reshaped by advancements in surgical techniques, drug therapies, and medical device innovation. Minimally invasive surgical procedures such as ureteroscopy, percutaneous nephrolithotomy (PCNL), laser lithotripsy, and laparoscopic urological reconstructions are enabling faster recovery, reduced hospital stays, and better patient outcomes. These approaches are particularly valuable for treating obstructive uropathy caused by stones, tumors, or anatomical abnormalities. On the pharmacologic front, alpha-blockers, antimuscarinics, and newer agents like beta-3 adrenergic agonists are expanding the arsenal of therapies used to treat bladder outlet obstruction and overactive bladder syndromes. Meanwhile, the use of botulinum toxin injections and sacral nerve stimulation is gaining ground in managing neurogenic uropathy. Catheter technologies are also evolving, with the introduction of antimicrobial, hydrophilic-coated, and intermittent catheters that reduce infection risks and improve patient comfort. Furthermore, wearable urinary sensors, portable bladder scanners, and remote patient monitoring tools are playing a growing role in post-treatment surveillance and chronic uropathy management. Digital platforms now support patient adherence and symptom tracking, while innovations in 3D imaging and navigation systems are enhancing surgical precision. Together, these developments are creating a more personalized and technologically integrated treatment environment that empowers both patients and providers to manage uropathy more effectively and efficiently.

Can Preventive Care and Early Intervention Strategies Redefine the Long-Term Approach to Uropathy?

Preventive care is increasingly becoming central to uropathy treatment strategies, especially in healthcare systems focused on reducing avoidable hospitalizations, surgical interventions, and chronic renal complications. Early detection through regular screening for kidney function, urinary flow obstruction, or bladder dysfunction is enabling clinicians to intervene before irreversible damage occurs. Educational efforts targeting at-risk populations-such as diabetics, spinal cord injury patients, and older adults-are promoting early reporting of symptoms like urinary hesitancy, frequency, retention, and incontinence. Meanwhile, lifestyle interventions including dietary modifications, hydration management, pelvic floor exercises, and weight control are being promoted as first-line strategies to reduce uropathy onset or progression. These approaches are particularly effective in managing lower urinary tract symptoms (LUTS) and mild forms of neurogenic bladder or detrusor overactivity. In pediatrics, timely correction of congenital uropathies through non-invasive imaging and minimally traumatic surgical repair is minimizing the risk of long-term renal impairment. Telemedicine is also playing a growing role in facilitating preventive uropathy care through remote consultations, early diagnostics, and digital adherence tools. As more clinical evidence supports the economic and quality-of-life benefits of early intervention, both payers and providers are adopting preventive care protocols as part of comprehensive uropathy management-reducing the overall burden on healthcare infrastructure while improving patient outcomes in the long run.

What Factors Are Driving the Sustained Growth of the Global Uropathy Treatment Market?

The growth in the uropathy treatment market is driven by a convergence of demographic, clinical, technological, and systemic factors that reflect broader trends in chronic disease management and personalized care. A primary growth driver is the rising incidence of chronic conditions-particularly diabetes, spinal cord injuries, neurological disorders, and cancers-that compromise urinary function, thus requiring long-term uropathy treatment. Aging populations across North America, Europe, and Asia-Pacific are further contributing to a growing base of patients requiring urological interventions. In response, healthcare systems are expanding their urology service lines and investing in surgical infrastructure, diagnostics, and outpatient care models to meet rising demand. The evolution of minimally invasive and robotic-assisted surgical techniques is improving access to advanced treatment options, particularly in high-volume centers. Regulatory approvals of new drugs and devices, combined with favorable reimbursement policies, are enhancing market accessibility and affordability. Technological innovations in urodynamics, catheter design, and neuromodulation are further expanding therapeutic options across different severity levels of uropathy. Additionally, the shift toward outpatient procedures, home-based care, and telehealth-supported follow-up is helping reduce hospitalization costs while ensuring continuity of care. Patient education campaigns and destigmatization efforts are also encouraging earlier engagement with healthcare systems, leading to higher diagnosis and treatment rates. As these forces continue to align, the global uropathy treatment market is expected to see sustained, long-term growth driven by rising clinical need, evolving treatment paradigms, and expanding access to multidisciplinary, tech-enabled care solutions.

SCOPE OF STUDY:

The report analyzes the Uropathy Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Stents, Devices); End-Use (Hospitals & Clinics, Ambulatory Surgery Centers, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

  • AngioDynamics
  • Applied Medical
  • Argon Medical Devices, Inc.
  • Astellas Pharma Inc.
  • B. Braun Melsungen AG
  • Bayer AG
  • Becton, Dickinson and Company (BD)
  • Boston Scientific Corporation
  • Cook Medical
  • C. R. Bard, Inc. (a subsidiary of BD)
  • GlaxoSmithKline Pharmaceuticals Ltd.
  • Inceler Medikal Co. Ltd.
  • KARL STORZ
  • Merit Medical Systems, Inc.
  • Olympus Corporation
  • optimed
  • Pfizer Inc.
  • Purdue Pharma
  • Sanofi
  • Teleflex Incorporated

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Uropathy Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Urological Disorders Globally Spurs Demand for Advanced Uropathy Treatments
    • Growing Incidence of Diabetes, Spinal Injuries, and Neurological Conditions Expands the Uropathy Patient Pool
    • Increased Preference for Non-Invasive and Minimally Invasive Therapies Strengthens Business Case for Modern Treatment Options
    • Integration of Digital Health Tools and Remote Monitoring Technologies Enhances Management of Chronic Uropathy
    • Pharmaceutical Advancements and Targeted Drug Therapies Propel Innovation in Symptom-Specific Uropathy Treatment
    • Rising Awareness of Bladder and Kidney Health Throws Spotlight on Early Diagnosis and Preventive Intervention
    • Expansion of Multidisciplinary Care Models Drives Adoption of Comprehensive Uropathy Management Protocols
    • Improved Access to Urological Services in Emerging Markets Generates New Opportunities for Treatment Expansion
    • Adoption of Neuromodulation and Botulinum Toxin Therapies Sustains Growth in Refractory and Complex Uropathy Cases
    • Technological Progress in Imaging and Urodynamic Testing Improves Diagnostic Precision and Treatment Personalization
    • Patient Demand for Fertility-Preserving and Organ-Conserving Solutions Creates Growth in Younger Demographics
    • Telemedicine Integration in Urology Services Accelerates Treatment Reach in Underserved and Remote Regions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Uropathy Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Uropathy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Uropathy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Uropathy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Stents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Stents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Stents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Ambulatory Surgery Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Uropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • JAPAN
    • Uropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • CHINA
    • Uropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • EUROPE
    • Uropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Uropathy Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Uropathy Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Uropathy Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • FRANCE
    • Uropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • GERMANY
    • Uropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Uropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Spain 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Russia 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Uropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Uropathy Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Uropathy Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for Uropathy Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Uropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Australia 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • INDIA
    • Uropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: India 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: South Korea 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Uropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Uropathy Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Uropathy Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Latin America 15-Year Perspective for Uropathy Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Argentina 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Brazil 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Mexico 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Uropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Uropathy Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Uropathy Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Middle East 15-Year Perspective for Uropathy Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Iran 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Israel 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: UAE 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • AFRICA
    • Uropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Africa 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제